SNRIs are SSRIs plus one more transporter. Where SSRIs block only SERT, SNRIs block both SERT and NET — the serotonin reuptake transporter and the norepinephrine reuptake transporter. Adding norepinephrine to the picture does three clinically useful things: it adds energy and focus, it strengthens descending pain modulation, and it raises blood pressure. That last item is the price.
- Class
- Serotonin-Norepinephrine Reuptake Inhibitors
- Mechanism
- Block both SERT and NET; dose-dependent NET inhibition (more prominent at higher doses)
- Typical dose
- Class-dependent
- Half-life
- Class-dependent
- FDA indications
- MDD, GAD, panic disorder, social anxiety; pain syndromes (duloxetine for fibromyalgia, diabetic neuropathy, chronic musculoskeletal pain)
- Key adverse effects
- Similar to SSRIs plus: dose-dependent BP elevation, increased sweating, sometimes more activation
- Representative agents
- Venlafaxine, desvenlafaxine, duloxetine, levomilnacipran
Black box: Suicidal thinking/behavior in pediatric and young adult patients
Dual mechanism may help when SSRIs partial response. Particularly useful for pain comorbidity. Monitor blood pressure during titration.
Four agents anchor the class: venlafaxine, desvenlafaxine, duloxetine, and levomilnacipran. They differ in NET selectivity, half-life, and indication breadth, but the framework is shared.
The most important fact about SNRIs is that their mechanism is dose-dependent. At low doses, an SNRI is mostly an SSRI — the SERT inhibition predominates and the NET effect is minimal. As the dose climbs, NET inhibition becomes meaningful. At very high doses, especially with venlafaxine, there's even some dopamine reuptake inhibition. This means the patient on venlafaxine 75 milligrams is essentially on an SSRI; the patient on 300 milligrams is on a full SNRI with some DA activity. The same drug, behaving differently at different doses.
That has clinical implications. The energy and focus benefits of SNRIs really emerge at moderate-to-high doses. So does the blood pressure effect. The BP rise is the central tolerability concern. Baseline BP before starting, recheck at each dose escalation, and a relative contraindication at higher doses in patients with uncontrolled hypertension. The patient who needs SNRI breadth but has poorly controlled BP needs a conversation about whether the cardiovascular cost is worth the psychiatric benefit, or whether to optimize BP first.
SNRIs add norepinephrine reuptake blockade to the SSRI mechanism, with the norepinephrine effect emerging dose-dependently — a clean example of sequential receptor engagement by dose.
Mechanism note: The defining SNRI principle is dose-dependent dual mechanism — the norepinephrine effect is recruited only as the dose climbs. The clinician choosing an SNRI must titrate to actually reach the second mechanism.
The pain story is the SNRI differentiator. The brain's endogenous pain inhibition system — descending pathways from brainstem nuclei like the locus coeruleus and raphe down to the spinal cord — is serotonergic and noradrenergic. By boosting both transmitters, SNRIs strengthen that descending pain modulation. Duloxetine in particular has FDA approvals for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. The pain effect is independent of mood — euthymic patients with chronic pain can benefit. When depression and chronic pain coexist, an SNRI often outperforms an SSRI for the combined picture.
Side effects share the SSRI profile — GI early, sexual dysfunction at therapeutic doses, sweating, the usual texture — and add a few signatures. Increased sweating is more prominent. Activation is more common. Discontinuation syndrome is severe with the short-half-life agents (venlafaxine, paroxetine's territory). Constipation is more common than with SSRIs.
Use SNRIs when you want SSRI-like serotonergic effect plus energy, plus pain coverage, plus a willingness to monitor BP. Use SSRIs first for uncomplicated depression and anxiety where the extra mechanism isn't needed. The decision isn't ideological — it's about matching the drug's mechanism to the patient's specific clinical needs.